NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis

Trends in Immunology

Volumn 28, Issue 11, 2007, Pages 491-496

  Terabe, Masaki ^a   Berzofsky, Jay A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER IMMUNOTHERAPY; HUMAN; IMMUNOREGULATION; IMMUNOSURVEILLANCE; NATURAL KILLER T CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD1; HUMANS; IMMUNE TOLERANCE; KILLER CELLS, NATURAL; NEOPLASMS; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 36048995442     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2007.05.008     Document Type: Review

References (73)

1. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23 (2005) 877-900
2. Taniguchi M., et al. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21 (2003) 483-513
3. Godfrey D.I., et al. NKT cells: what's in a name?. Nat. Rev. Immunol. 4 (2004) 231-237
4. Kawano T., et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278 (1997) 1626-1629
5. Wu D.Y., et al. Cross-presentation of Disialoganglioside GD3 to Natural Killer T Cells. J. Exp. Med. 198 (2003) 173-181
6. Gumperz J.E., et al. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 12 (2000) 211-221
7. Zhou D., et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 306 (2004) 1786-1789
8. Kinjo Y., et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat. Immunol. 7 (2006) 978-986
9. Kinjo Y., et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434 (2005) 520-525
10. Sriram V., et al. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur. J. Immunol. 35 (2005) 1692-1701
11. Porubsky S., et al. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 5977-5982
12. Speak A.O., et al. Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 5971-5976
13. Stetson D.B., et al. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J. Exp. Med. 198 (2003) 1069-1076
14. Matsuda J.L., et al. Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8395-8400
15. Mattner J., et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434 (2005) 525-529
16. Vincent M.S., et al. CD1-dependent dendritic cell instruction. Nat. Immunol. 3 (2002) 1163-1168
17. Cardell S., et al. CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice. J. Exp. Med. 182 (1995) 993-1004
18. Baron J.L., et al. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 16 (2002) 583-594
19. Exley M.A., et al. Cutting edge: Compartmentalization of Th1-like noninvariant CD1d-reactive T cells in hepatitis C virus-infected liver. J. Immunol. 168 (2002) 1519-1523
20. Fuss I.J., et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113 (2004) 1490-1497
21. Jahng A., et al. Prevention of Autoimmunity by Targeting a Distinct, Noninvariant CD1d-reactive T Cell Population Reactive to Sulfatide. J. Exp. Med. 199 (2004) 947-957
22. Duarte N., et al. Prevention of diabetes in nonobese diabetic mice mediated by CD1d-restricted nonclassical NKT cells. J. Immunol. 173 (2004) 3112-3118
23. Mallevaey T., et al. Invariant and Noninvariant Natural Killer T Cells Exert Opposite Regulatory Functions on the Immune Response during Murine Schistosomiasis. Infect. Immun. 75 (2007) 2171-2180
24. Exley M.A., et al. A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses. J. Immunol. 167 (2001) 5531-5534
25. Gadola S.D., et al. Valpha24-JalphaQ-independent, CD1d-restricted recognition of alpha-galactosylceramide by human CD4(+) and CD8alphabeta(+) T lymphocytes. J. Immunol. 168 (2002) 5514-5520
26. Van Rhijn I., et al. CD1d-restricted T cell activation by nonlipidic small molecules. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 13578-13583
27. Kitamura H., et al. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)- 12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189 (1999) 1121-1128
28. Tomura M., et al. A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J. Immunol. 163 (1999) 93-101
29. Yang Y.F., et al. Requirement for IFN-gamma in IL-12 production induced by collaboration between v(alpha)14(+) NKT cells and antigen-presenting cells. Int. Immunol. 12 (2000) 1669-1675
30. Hayakawa Y., et al. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J. Immunol. 166 (2001) 6012-6018
31. Nakagawa R., et al. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J. Immunol. 166 (2001) 6578-6584
32. Miyamoto K., et al. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413 (2001) 531-534
33. Ambrosino E., et al. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J. Immunol. 179 (2007) 5126-5136
34. Akbari O., et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat. Med. 9 (2003) 582-588
35. Akbari O., et al. CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. N. Engl. J. Med. 354 (2006) 1117-1129
36. Smyth M.J., et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191 (2000) 661-668
37. Crowe N.Y., et al. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196 (2002) 119-127
38. Crowe N.Y., et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 202 (2005) 1279-1288
39. Lee P.T., et al. Distinct functional lineages of human Va24 natural killer cells. J. Exp. Med. 195 (2002) 637-641
40. Gumperz J.E., et al. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195 (2002) 625-636
41. Stewart T.J., et al. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells. Cancer Res. 63 (2003) 3058-3060
42. Tachibana T., et al. Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin. Cancer Res. 11 (2005) 7322-7327
43. Metelitsa L.S., et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J. Exp. Med. 199 (2004) 1213-1221
44. Matsui S., et al. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J. Immunol. 163 (1999) 184-193
45. Terabe M., et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1 (2000) 515-520
46. Terabe M., et al. Transforming Growth Factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block Cytotoxic T Lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198 (2003) 1741-1752
47. Terabe M., et al. Role of IL-13 in negative regulation of anti-tumor immunity. Cancer Immunol. Immunother. 53 (2003) 79-85
48. Fichtner-Feigl S., et al. IL-13 signaling through the IL-13alpha(2) receptor is involved in induction of TGF-beta(1) production and fibrosis. Nat. Med. 12 (2005) 99-106
49. Park J.M., et al. Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. Int. J. Cancer 114 (2004) 80-87
50. Terabe M., et al. A nonclassical non-Va14Ja18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J. Exp. Med. 202 (2005) 1627-1633
51. Ostrand-Rosenberg S., et al. Resistance to metastatic disease in Stat6-deficient mice requires hematopoietic and non-hematopoietic cells and is IFNγ-dependent. J. Immunol. 169 (2002) 5796-5804
52. Terabe M., et al. CD1d-restricted NKT cells can down-regulate tumor immunosurveillance independent of IL-4R-STAT6 or TGF-β. Cancer Res. 66 (2006) 3869-3875
53. Subleski J.J., et al. Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver. Cancer Res. 66 (2006) 11005-11012
54. Roberts D.D. Sulfatide-binding proteins. Chem. Phys. Lipids 42 (1986) 173-183
55. Godfrey D.I., and Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114 (2004) 1379-1388
56. Ortaldo J.R., et al. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J. Immunol. 172 (2004) 943-953
57. Ilan Y., et al. Alleviation of acute and chronic graft-versus-host disease in a murine model is associated with glucocerebroside-enhanced natural killer T lymphocyte plasticity. Transplantation 83 (2007) 458-467
58. Zigmond E., et al. Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders. Gut 56 (2007) 82-89
59. Renukaradhya G.J., et al. Inhibition of antitumor immunity by invariant natural killer T cells in a T-cell lymphoma model in vivo. Int J Cancer 118 (2006) 3045-3053
60. Duthie M.S., et al. Critical proinflammatory and anti-inflammatory functions of different subsets of CD1d-restricted natural killer T cells during Trypanosoma cruzi infection. Infect. Immun. 73 (2005) 181-192
61. Tamada K., et al. Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes. J. Immunol. 158 (1997) 4846-4854
62. Yanagisawa K., et al. Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J. Immunol. 168 (2002) 6494-6499
63. Tahir S.M., et al. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J. Immunol. 167 (2001) 4046-4050
64. van der Vliet H.J., et al. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells. Cancer Res. 63 (2003) 4101-4106
65. Kenna T., et al. NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J. Immunol. 171 (2003) 1775-1779
66. Dhodapkar M.V., et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197 (2003) 1667-1676
67. Molling J.W., et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J. Clin. Oncol. 25 (2007) 862-868
68. Behar S.M., et al. Diverse TCRs recognize murine CD1. J. Immunol. 162 (1999) 161-167
69. Halder R.C., et al. Type II NK T cell-mediated anergy induction in type I NK T cells prevents inflammatory liver disease. J. Clin. Invest. 117 (2007) 2302-2312
70. Nishikawa H., et al. CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10902-10906
71. Azuma T., et al. Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res. 63 (2003) 4516-4520
72. Liu R., et al. Cooperation of Invariant NKT Cells and CD4+CD25+ T Regulatory Cells in the Prevention of Autoimmune Myasthenia. J. Immunol. 175 (2005) 7898-7904
73. Park S.H., et al. The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J. Exp. Med. 193 (2001) 893-904